Merrimack Pharmaceuticals Revenue and Competitors

Boston, MA USA

Location

$288M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Merrimack Pharmaceuticals's estimated annual revenue is currently $7.5M per year.(i)
  • Merrimack Pharmaceuticals's estimated revenue per employee is $115,385
  • Merrimack Pharmaceuticals's total funding is $288M.

Employee Data

  • Merrimack Pharmaceuticals has 65 Employees.(i)
  • Merrimack Pharmaceuticals grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of immunology and oncology. Founded by leading scientists from MIT and Harvard, the company’s proprietary “Network Biology” discovery platform enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately held company based in Cambridge, Massachusetts.

keywords:N/A

$288M

Total Funding

65

Number of Employees

$7.5M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Merrimack Pharmaceuticals News

2022-04-17 - Merrimack Pharmaceuticals (NASDAQ:MACK) Research Coverage ...

Merrimack Pharmaceuticals, Inc operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge,...

2022-04-13 - Merrimack Pharmaceuticals (NASDAQ:MACK) Now Covered by ...

Merrimack Pharmaceuticals, Inc operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge,...

2022-04-06 - HIV drug stabilizes disease progression in metastatic colorectal cancer

DTT has received consulting fees from Tekla Capital Management, Ikena Oncology, NanoString Technologies, Pfizer, Merrimack Pharmaceuticals,...

2021-03-10 - Merrimack Reports Full Year 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 10, 2021-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2020 financial results for the period ended December 31, 2020. “We are pleased that both Ipsen Pharmaceuticals and Elevation Oncology co ...

2018-07-02 - Merrimack Raises $25 Million Debt Facility with Hercules Capital

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the closing of a $25 million term loan with Hercules Capital (NYSE: HTGC), $15 million of which was funded at closing today. Merrimack's current cash and cash e ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.3M6548%N/A
#2
$10.1M65-2%N/A
#3
$7.6M6527%N/A
#4
$8.2M6559%N/A
#5
$5.9M65-8%N/A